周子超^1;2;徐晓玲²;江海涛³;朱慧能⁴;陈奇勋⁵;杜向慧⁶;裘国勤⁶;孙才兴⁷;范云²

• 1:浙江中医药大学第二临床医学院，浙江 杭州 310053中国科学院大学附属肿瘤医院(浙江省肿瘤医院)胸部肿瘤内科，浙江 杭州 310022中国科学院大学附属肿瘤医院(浙江省肿瘤医院)放射科，浙江 杭州 310022中国科学院大学附属肿瘤医院(浙江省肿瘤医院)病理科，浙江 杭州 310022中国科学院大学附属肿瘤医院(浙江省肿瘤医院)胸部肿瘤外科，浙江 杭州 310022中国科学院大学附属肿瘤医院(浙江省肿瘤医院)胸部放疗科，浙江 杭州 310022中国科学院大学附属肿瘤医院(浙江省肿瘤医院)神经外科，浙江 杭州 310022

摘要(Abstract)：

本文介绍1例原发性肺淋巴上皮瘤样癌（lymphoepithelioma-like carcinoma，LELC）的多学科团队（multidisciplinary team，MDT）诊疗过程。该患者经支气管活检病理诊断右肺LELC，结合影像学检查结果合并肝转移可能大，无驱动基因突变。第1次MDT讨论后行一线GP方案（吉西他滨+顺铂）化疗，2个周期后评估示肺内病灶部分缓解，肝内病灶未见缩小。第2次MDT讨论后，行CT引导下经皮穿刺肝内病灶未见肿瘤细胞，暂除外肝转移，肺病灶局限，遂行右肺癌根治术及淋巴结清扫术。术后6个月新发脑转移，第3次MDT讨论后行局部脑转移瘤切除术序贯全脑放疗。疾病稳定14个月后肝脏病灶进展，二线予免疫检查点抑制剂纳武利尤单抗单药免疫治疗，无进展生存期26个月。该晚期原发LELC患者至今总生存期达53个月。本例报道提示，经MDT讨论后行综合治疗，能确保患者获得更合适的治疗，以取得较长的疾病控制时间和长期的生存获益。

关键词(KeyWords)： 肺癌;非小细胞肺癌;肺淋巴上皮瘤样癌;多学科团队;诊断;免疫检查点抑制剂;综合治疗

Abstract:

Keywords:

基金项目(Foundation):

作者(Author): 周子超^1;2;徐晓玲²;江海涛³;朱慧能⁴;陈奇勋⁵;杜向慧⁶;裘国勤⁶;孙才兴⁷;范云²

Email:

DOI: 10.13267/j.cnki.syzlzz.2021.062

参考文献(References)：

• [1] Goldstraw P, Chansky K, Crowley J, et al. The IASLC Lung Cancer Staging Project:Proposals for revision of the TNM Stage Groupings in the forthcoming (eighth) edition of the TNM Classification for Lung Cancer[J]. J Thorac Oncol, 2016, 11(1):39-51.
  [2] Fang W, Hong S, Chen N, et al. PD-L1 is remarkably over-expressed in EBV-associated pulmonary lymphoepithelioma-like carcinoma and related to poor disease-free survival[J]. Oncotarget, 2015, 6(32):33019-33032.
  [3] Sathirareuangchai S, Hirata K. Pulmonary lymphoepithelioma-like carcinoma[J]. Arch Pathol Lab Med, 2019, 143(8):1027-1030.
  [4] He J, Shen J, Pan H, et al. Pulmonary lymphoepithelioma-like carcinoma:a Surveillance, Epidemiology, and End Results database analysis[J]. J Thorac Dis, 2015, 7(12):2330-2338.
  [5] Castro CY, Ostrowski ML, Barrios R, et al. Relationship between Epstein-Barr virus and lymphoepithelioma-like carcinoma of the lung:a clinicopathologic study of 6 cases and review of the literature[J]. Hum Pathol, 2001, 32(8):863-872.
  [6] Huang CJ, Feng AC, Fang YF, et al. Multimodality treatment and long-term follow-up of the primary pulmonary lymphoepithelioma-like carcinoma[J]. Clin Lung Cancer, 2012, 13(5):359-362.
  [7] Scagliotti GV, Parikh P, von Pawel J, et al. Phase Ⅲ study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer[J]. J Clin Oncol, 2008, 26(21):3543-3551.
  [8] Lin Z, Fu S, Zhou Y, et al. First-line platinum-based chemotherapy and survival outcomes in locally advanced or metastatic pulmonary lymphoepithelioma-like carcinoma[J]. Lung Cancer, 2019, 137(9):100-107.
  [9] Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours:revised RECIST guideline (version 1.1)[J]. Eur J Cancer, 2009, 45(2):228-247.
  [10] Ricco A, Davis J, Rate W, et al. Lung metastases treated with stereotactic body radiotherapy:the RSSearch(R) patient Registry's experience[J]. Radiat Oncol, 2017, 12(1):35.
  [11] Salah S, Tanvetyanon T, Abbasi S. Metastatectomy for extra-cranial extra-adrenal non-small cell lung cancer solitary metastases:systematic review and analysis of reported cases[J]. Lung Cancer, 2012, 75(1):9-14.
  [12] Ewend MG, Morris DE, Carey LA, et al. Guidelines for the initial management of metastatic brain tumors:role of surgery, radiosurgery, and radiation therapy[J]. J Natl Compr Canc Netw, 2008, 6(5):505-513; quiz 14.
  [13] Patchell RA, Tibbs PA, Walsh JW, et al. A randomized trial of surgery in the treatment of single metastases to the brain[J]. N Engl J Med, 1990, 322(8):494-500.
  [14] Borghaei H, Paz-Ares L, Horn L, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer[J]. N Engl J Med, 2015, 373(17):1627-1639.
  [15] Kim C, Rajan A, DeBrito PA, et al. Metastatic lymphoepithelioma-like carcinoma of the lung treated with nivolumab:a case report and focused review of literature[J]. Transl Lung Cancer Res, 2016, 5(6):720-726.
  [16] Anand A, Zayac A, Curtiss C, et al. Pulmonary lymphoepithelioma-like carcinoma disguised as squamous cell carcinoma[J]. J Thorac Oncol, 2018, 13(5):e75-76.
  [17] Xie M, Wu X, Wang F, et al. Clinical significance of plasma Epstein-Barr virus DNA in pulmonary lymphoepithelioma-like carcinoma (LELC) patients[J]. J Thorac Oncol, 2018, 13(2):218-227.
  [18] Xie Z, Liu L, Lin X, et al. A multicenter analysis of genomic profiles and PD-L1 expression of primary lymphoepithelioma-like carcinoma of the lung[J]. Mod Pathol, 2020, 33(4):626-638.
  [19] Hong S, Liu D, Luo S, et al. The genomic landscape of Epstein-Barr virus-associated pulmonary lymphoepithelioma-like carcinoma[J]. Nat Commun, 2019, 10(1):3108.
  [20] Liang Y, Wang L, Zhu Y, et al. Primary pulmonary lymphoepithelioma-like carcinoma:fifty-two patients with long-term follow-up[J]. Cancer, 2012, 118(19):4748-4758.
  [21] Hu Y, Ren S, Liu Y, et al. Pulmonary Lymphoepithelioma-like carcinoma:a mini-review[J]. Onco Targets Ther, 2020, 13:3921-3929.
  [22] Bremnes RM, Busund LT, Kilvaer TL, et al. The role of tumor-infiltrating lymphocytes in development, progression, and prognosis of non-small cell lung cancer[J]. J Thorac Oncol, 2016, 11(6):789-800.
  [23] Fu Y, Zheng Y, Wang PP, et al. Pulmonary lymphoepithelioma-like carcinoma treated with immunotherapy or chemotherapy:a single institute experience[J]. Onco Targets Ther, 2021, 14:1073-1081.
  [24] Wu Z, Xian X, Wang K, et al. Immune checkpoint blockade therapy may be a feasible option for primary pulmonary lymphoepithelioma-like carcinoma[J]. Front Oncol, 2021, 11:626566.
  [25] Sasaki A, Kato T, Ujiie H, et al. Primary pulmonary lymphoepithelioma-like carcinoma with positive expression of Epstein-Barr virus and PD-L1:A case report[J]. Int J Surg Case Rep, 2021, 79(1):431-435.
  [26] Qiu ZX, Zhou P, Wang K. Primary pulmonary lymphoepithelioma-like carcinoma response favorably to nivolumab:a case report[J]. Onco Targets Ther, 2019, 12:8595-8600.
  [27] Zhou N, Lin Y, Peng X, et al. Thorough survey and analysis of pulmonary lymphoepithelioma-like carcinoma in Macau and multimodality treatment for advanced disease[J]. Lung Cancer, 2019, 138(10):116-123.
  [28] Qin Y, Gao G, Xie X, et al. Clinical features and prognosis of pulmonary lymphoepithelioma-like carcinoma:summary of eighty-five cases[J]. Clin Lung Cancer, 2019, 20(3):e329-337.